Sublingual oral preparation of torasemide

An oral preparation, torasemide technology, applied in the medical field, can solve the problems of gastrointestinal irritation, obvious first-pass effect, narrow adaptability, etc., to speed up the onset time, expand the contact area, and reduce the amount of use. Effect

CN107157994AInactive Publication Date: 2017-09-15董鹏
5 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2017-09-15
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a sublingual oral preparation of torasemide. The sublingual oral preparation of torasemide comprises the following raw materials by weight: 15 to 35 parts of torasemide, 30 to 80 parts of a penetration enhancer, 35 to 55 parts of a disintegrating agent and 150 to 200 parts of a filler. According to the invention, a sublingual administration manner is employed for torasemide, so torasemide is prevented from entering in-vivo systemic circulation; and thus, the usage amount of torasemide is greatly lowered, and side effect of torasemide is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of medical technology, and more specifically relates to a method for improving the efficacy of sildenafil for treating sexual dysfunction. Background technique

[0002] Torasemide is a new generation of high-efficiency loop diuretics. More than 20 years of clinical application have proved that torasemide has a wide range of indications, a rapid, strong and long-lasting diuretic effect, and a low incidence of adverse reactions. It is a high-efficiency diuretic worthy of promotion in clinical practice. agent. Its structural formula is as follows:

[0003]

[0004] Torsemide has diuretic, Na+ and Cl- excretion effects, but does not significantly change glomerular filtration rate, renal plasma flow and acid-base balance. It acts on the thick ascending branch of the loop of Henle, interferes with the Na+ / K+ / 2Cl- symporting system of the luminal cell membrane, inhibits the reabsorption of Cl- and Na+, increases the con...

Examples

Embodiment 1

[0023] The sublingual oral preparation comprises the following raw materials in parts by weight: 25 parts by weight of torasemide, 60 parts by weight of chitosan, 45 parts by weight of crospovidone, and 170 parts by weight of mannitol, which are prepared by mixing and pressing into tablets.

Embodiment 2

[0025] The sublingual oral preparation comprises the following raw materials in parts by weight: 25 parts by weight of torasemide, 50 parts by weight of cyclodextrin, 35 parts by weight of croscarmellose sodium, and 190 parts by weight of mannitol, which are mixed and compressed into tablets.

Embodiment 3

[0027] Sublingual oral preparations, comprising the following raw materials in parts by weight: 25 parts by weight of torasemide, 80 parts by weight of oleic acid, 25 parts by weight of crospovidone, 20 parts by weight of croscarmellose sodium, and 150 parts by weight of sucrose , prepared by mixing tablets.